News Author: Christopher Palmer Publish date: September 6, 2018
Although the efficacy was similar, safety differed between the two regimens.
News Author: Christopher Palmer Publish date: September 5, 2018
Esketamine has shown promise in treating refractory depression when used with an oral antidepressant.
News Author: Christopher Palmer Publish date: August 28, 2018
Two phase 3 trials suggested that risankizumab can do more to improve quality of life, with similar safety.
News Author: Christopher Palmer Publish date: August 28, 2018
Certain forms of counseling interventions have shown promise in preventing perinatal depression in pregnant and postpartum women.
News Author: Christopher Palmer Publish date: August 21, 2018
Stiripentol (Diacomit) is a new way to treat this rare but potentially life-threatening form of epilepsy.
News Author: Christopher Palmer Publish date: August 20, 2018
Transcranial magnetic stimulation already is approved to treat refractory major depression and migraine with aura.
News Author: Christopher Palmer Publish date: August 20, 2018
A review of the Companion 2 driver system for temporary total artificial hearts showed higher mortality and strok...
News Author: Christopher Palmer Publish date: August 16, 2018
The approval is for the generic version of the most widely prescribed epinephrine autoinjector in the United States.
News Author: Christopher Palmer Publish date: August 16, 2018
Kalydeco (ivacaftor) treats the underlying cause of cystic fibrosis and previously was approved for patients aged 2 years and older.
News Author: Christopher Palmer Publish date: August 15, 2018
Ibalizumab can not only help decrease viral loads in patients with multidrug-resistant HIV type 1, but it also can help increase CD4 counts.
News Author: Christopher Palmer Publish date: August 14, 2018
“These findings, in a large COPD database, speak against the potential negative cardiovascular effects of olodaterol, as well as those of formotero...
News Author: Christopher Palmer Publish date: August 9, 2018
Safety and pharmacokinetics concentrations were comparable regardless of split or single dosing of daratumumab.
News Author: Christopher Palmer Publish date: August 9, 2018
The highest risks were for autism spectrum disorder and ADHD.
News Author: Christopher Palmer Publish date: August 8, 2018
Previously, the drug was indicated for certain cystic fibrosis patients aged 6 years and older, but now it is available for patients as young as 2 ...
News Author: Christopher Palmer Publish date: August 3, 2018
Azithromycin can lead to relapse and death when used to prevent an inflammatory lung condition in patients with blood or lymph node cancers who hav...
